Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.65 - $9.31 $58,125 - $116,375
-12,500 Reduced 47.53%
13,800 $67,000
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $106,904 - $206,080
18,400 Added 232.91%
26,300 $231,000
Q3 2023

Nov 14, 2023

SELL
$11.47 - $25.07 $118,141 - $258,221
-10,300 Reduced 56.59%
7,900 $90,000
Q2 2023

Aug 14, 2023

BUY
$24.7 - $37.61 $190,190 - $289,597
7,700 Added 73.33%
18,200 $460,000
Q1 2023

May 15, 2023

SELL
$18.36 - $35.27 $227,664 - $437,348
-12,400 Reduced 54.15%
10,500 $338,000
Q4 2022

Feb 14, 2023

BUY
$18.32 - $30.66 $340,752 - $570,276
18,600 Added 432.56%
22,900 $422,000
Q3 2022

Nov 14, 2022

SELL
$14.33 - $28.47 $67,351 - $133,809
-4,700 Reduced 52.22%
4,300 $116,000
Q2 2022

Aug 08, 2022

BUY
$11.52 - $20.4 $100,224 - $177,480
8,700 Added 2900.0%
9,000 $124,000
Q1 2022

May 16, 2022

SELL
$12.36 - $20.31 $100,116 - $164,511
-8,100 Reduced 96.43%
300 $6,000
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $58,562 - $130,989
-4,700 Reduced 35.88%
8,400 $137,000
Q3 2021

Nov 15, 2021

BUY
$25.78 - $33.21 $180,460 - $232,470
7,000 Added 114.75%
13,100 $365,000
Q2 2021

Aug 16, 2021

BUY
$26.8 - $31.84 $163,480 - $194,224
6,100 New
6,100 $181,000
Q1 2021

May 17, 2021

SELL
$24.03 - $29.97 $38,448 - $47,952
-1,600 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$23.41 - $28.34 $149,824 - $181,376
-6,400 Reduced 80.0%
1,600 $45,000
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $185,840 - $274,400
8,000 New
8,000 $201,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.